These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6369034)

  • 1. When should the stone patient be evaluated? Limited evaluation of single stone formers.
    Erickson SB
    Med Clin North Am; 1984 Mar; 68(2):461-8. PubMed ID: 6369034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When should the stone patient be evaluated? Early evaluation of single stone formers.
    Smith CL
    Med Clin North Am; 1984 Mar; 68(2):455-9. PubMed ID: 6369033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis and urolithiasis.
    Caudarella R; Vescini F; Buffa A; La Manna G; Stefoni S
    Urol Int; 2004; 72 Suppl 1():17-9. PubMed ID: 15133327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of a single calcium stone of renal origin. Clinical and laboratory characteristics of patients.
    Strauss AL; Coe FL; Parks JH
    Arch Intern Med; 1982 Mar; 142(3):504-7. PubMed ID: 7065787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Etiopathogenesis and clinical aspects of nephrolithiasis--at present].
    Ferrari L; Meschi M; Musini S; Frattini A; Savazzi GM
    Recenti Prog Med; 2003 Mar; 94(3):136-41. PubMed ID: 12677782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal Changes in Kidney Stone Composition and in Risk Factors Predisposing to Stone Formation.
    Xu LHR; Adams-Huet B; Poindexter JR; Maalouf NM; Moe OW; Sakhaee K
    J Urol; 2017 Jun; 197(6):1465-1471. PubMed ID: 28111301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium oxalate monohydrate binding protein: a diagnostic biomarker for calcium oxalate kidney stone formers.
    Asokan D; Kalaiselvi P; Muhammed Farooq S; Varalakshmi P
    Urol Res; 2004 Oct; 32(5):357-61. PubMed ID: 15365653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambulatory diagnostic evaluation of 389 recurrent renal stone formers. A proposal for clinical classification and investigation.
    Wikström B; Backman U; Danielson BG; Fellström B; Johansson G; Ljunghall S
    Klin Wochenschr; 1983 Jan; 61(2):85-90. PubMed ID: 6843037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of medical management strategies for nephrolithiasis.
    Lotan Y; Cadeddu JA; Roerhborn CG; Pak CY; Pearle MS
    J Urol; 2004 Dec; 172(6 Pt 1):2275-81. PubMed ID: 15538248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium restriction as initial conservative treatment for urinary stone disease.
    Yun SJ; Ha YS; Kim WT; Kim YJ; Lee SC; Kim WJ
    J Urol; 2010 Oct; 184(4):1372-6. PubMed ID: 20723924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the recurrent stone former.
    Chandhoke PS
    Urol Clin North Am; 2007 Aug; 34(3):315-22. PubMed ID: 17678982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary style and acid load in an Italian population of calcium kidney stone formers.
    Vezzoli G; Dogliotti E; Terranegra A; Arcidiacono T; Macrina L; Tavecchia M; Pivari F; Mingione A; Brasacchio C; Nouvenne A; Meschi T; Cusi D; Spotti D; Montanari E; Soldati L
    Nutr Metab Cardiovasc Dis; 2015 Jun; 25(6):588-93. PubMed ID: 25921845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic evaluation: who, when and how often.
    De Coninck V; Keller EX; Traxer O
    Curr Opin Urol; 2019 Jan; 29(1):52-64. PubMed ID: 30325869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional evaluation in patients with kidney calculi].
    Stojimirović B
    Srp Arh Celok Lek; 1998; 126(9-10):394-8. PubMed ID: 9863414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors.
    Caudarella R; Vescini F; Buffa A; Sinicropi G; Rizzoli E; La Manna G; Stefoni S
    J Nephrol; 2003; 16(2):260-6. PubMed ID: 12768074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical studies on the recurrence of urolithiasis: (1). Influence of diet on urinary excretion of the stone forming constituents].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1987 Sep; 33(9):1321-30. PubMed ID: 3434487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary metabolic evaluation of stone formers-a Malaysian perspective.
    Hong YH; Dublin N; Razack AH; Mohd MA; Husain R
    Urology; 2012 Sep; 80(3):529-34. PubMed ID: 22578827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.